Pulmatrix, Inc.

PULM Healthcare Biotechnology

Pulmatrix, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.8 million, up 6.96% from fiscal 2023.

Revenue
−99.9%
EPS
+31.0%
Free cash flow
+41.3%

Quarter to June 2026, against a year earlier

1.39 0.01 −0.71%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−27.85
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
4.70 4.96 12.55 19.97
Net Debt/EBITDA
2.74 3.11 4.50 5.54
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.30) (0.29) (0.19) (0.28)
Book value per Share
0.70 0.98 1.04 1.30
Free Cash Flow
(1.11) (1.07) (0.71) (1.03)
Other line items

Show all line items

Columns are period end dates